CreativeOne Wealth LLC Makes New $293,000 Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CreativeOne Wealth LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,223 shares of the company’s stock, valued at approximately $293,000.

Several other large investors also recently bought and sold shares of the stock. Signaturefd LLC raised its stake in Neurocrine Biosciences by 502.5% in the third quarter. Signaturefd LLC now owns 2,386 shares of the company’s stock valued at $268,000 after buying an additional 1,990 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Neurocrine Biosciences by 0.7% in the third quarter. Victory Capital Management Inc. now owns 69,832 shares of the company’s stock valued at $7,856,000 after purchasing an additional 463 shares in the last quarter. Jump Financial LLC purchased a new position in Neurocrine Biosciences in the third quarter valued at approximately $887,000. Cookson Peirce & Co. Inc. acquired a new stake in Neurocrine Biosciences during the third quarter worth approximately $1,293,000. Finally, Metis Global Partners LLC lifted its position in shares of Neurocrine Biosciences by 4.7% during the 3rd quarter. Metis Global Partners LLC now owns 2,361 shares of the company’s stock worth $266,000 after buying an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded down $1.11 on Friday, hitting $139.40. 423,935 shares of the company were exchanged, compared to its average volume of 730,788. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37. The firm has a market capitalization of $14.03 billion, a P/E ratio of 38.40 and a beta of 0.28. The company’s 50 day moving average price is $138.66 and its 200-day moving average price is $131.88.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.17 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric Benevich sold 19,818 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $135.51, for a total transaction of $36,994.23. Following the completion of the sale, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,017,273.57. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Benevich sold 19,818 shares of Neurocrine Biosciences stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now directly owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The disclosure for this sale can be found here. Insiders have sold 180,770 shares of company stock worth $25,047,308 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NBIX shares. Evercore ISI initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday, May 14th. They set an “outperform” rating and a $175.00 target price for the company. Wedbush restated an “outperform” rating and set a $147.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Mizuho boosted their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Oppenheimer upped their target price on Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Canaccord Genuity Group upped their price objective on Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $148.96.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.